indications for glp 1 agonists The GLP-1 and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy What to know about the

Boer et al, 2023)

In a randomised controlled trial with over 1800 participants comparing tirzepatide to semaglutide, the tirzepatide group reported more serious adverse events (5-7% VS 3%) and higher discontinuation rates due to adverse events (6-8.5% VS 4%)

We need to treat it like one, just like we treat hypertension or high cholesterol. Two GLP-1 agonists and one dual GIP/GLP-1 agonist are currently FDA-approved to treat obesity

The Standards note that the goal of provider-patient communication is to establish a collaborative relationship that allows for the assessment of self-management barriers without blaming patients for noncompliance or nonadherence when outcomes are less than optimal

24 This opens the door to exploring these novel compounds as potential therapeutic agents in a broader range of conditions

If deemed medically necessary, many GLP-1 medications are often covered by insurance